Magdalena KuÅºma-Kozakiewicz

List of Publications by Year
in descending order

37 papers	587 citations	758635 12 h-index	676716 22 g-index
37 all docs	37 docs citations	37 times ranked	953 citing authors

#	Article	IF	Citations
1	Caregiversâ€™ divergent perspectives on patientsâ€™ well-being and attitudes towards hastened death in Germany, Poland and Sweden. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 252-262.	1.1	2
2	SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Scientific Reports, 2022, 12, 103.	1.6	48
3	Physical activity in patients with amyotrophic lateral sclerosis: Prevalence, patientsâ€™ perspectives and relation to the motor performance. NeuroRehabilitation, 2022, 50, 433-443.	0.5	2
4	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.1	3
5	Putative founder effect in the Polish, Iranian and United States populations for the L144S SOD1 mutation associated with slowly uniform phenotype of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 80-85.	1.1	6
6	Dyslipidemia in patients with amyotrophic lateral sclerosis â€“ a case control retrospective study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 195-205.	1.1	8
7	ALS and fertility: does ALS affect number of children patients have?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 94-100.	1.1	0
8	Cardiovascular comorbidities in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 421, 117292.	0.3	10
9	Motor neuron disease beginning with frontotemporal dementia: clinical features and progression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 508-516.	1.1	7
10	Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?. Frontiers in Neurology, 2021, 12, 761355.	1.1	12
11	Peripheral neuropathy in ALS: phenotype association. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1133-1134.	0.9	3
12	Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurological Sciences, 2020, 41, 1115-1124.	0.9	15
13	Spreading in ALS: The relative impact of upper and lower motor neuron involvement. Annals of Clinical and Translational Neurology, 2020, 7, 1181-1192.	1.7	34
14	Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based caseâ€“control study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 671-672.	0.9	3
15	Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. Journal of Neurology, 2020, 267, 2130-2141.	1.8	23
16	Healthcare provision in amyotrophic lateral sclerosis: procedures, queries and pitfalls in Germany and Poland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 193-202.	1.1	4
17	Gastrostomy and mechanical ventilation in amyotrophic lateral sclerosis: how best to support the decision-making process?. Neurologia I Neurochirurgia Polska, 2020, 54, 366-377.	0.6	10
18	Influence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population. , 2019, 10, 205.		18

#	Article	IF	Citations
19	ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 293.	1.1	54
20	An observational study on quality of life and preferences to sustain life in locked-in state. Neurology, 2019, 93, e938-e945.	1.5	41
21	Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis. Neurologia I Neurochirurgia Polska, 2019, 53, 99-112.	0.6	6
22	Edaravone in the treatment of amyotrophic lateral sclerosis. Neurologia I Neurochirurgia Polska, 2018, 52, 124-128.	0.6	3
23	Intraspinal Transplantation of the Adipose Tissue-Derived Regenerative Cells in Amyotrophic Lateral Sclerosis in Accordance with the Current Expertsâ€™ Recommendations: Choosing Optimal Monitoring Tools. Stem Cells International, 2018, 2018, 1-16.	1.2	13
24	Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. Journal of Neurology, 2018, 265, 1600-1606.	1.8	34
25	International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 505-510.	1.1	17
26	Validation of qPCR reference genes in lymphocytes from patients with amyotrophic lateral sclerosis. PLoS ONE, 2017, 12, e0174317.	1.1	14
27	Existential decision-making in a fatal progressive disease: how much do legal and medical frameworks matter?. BMC Palliative Care, 2017, 16, 80.	0.8	12
28	Alteration of Motor Protein Expression Involved in Bidirectional Transport in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2016, 16, 235-244.	0.8	9
29	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.1	84
30	Recurrent K3E mutation in Cu/Zn superoxide dismutase gene associated with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 608-614.	1.1	7
31	SMN1 gene duplications are more frequent in patients with progressive muscular atrophy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 457-462.	1.1	8
32	Dynactin Deficiency in the CNS of Humans with Sporadic ALS and Mice with Genetically Determined Motor Neuron Degeneration. Neurochemical Research, 2013, 38, 2463-2473.	1.6	31
33	Kinesin Expression in the Central Nervous System of Humans and Transgenic hSOD1G93AMice with Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2013, 12, 71-80.	0.8	11
34	Changes in kinesin expression in the CNS of mice with dynein heavy chain 1 mutation. Acta Biochimica Polonica, 2013, 60, 51-5.	0.3	3
35	Recurrent G41S mutation in Cu/Zn superoxide dismutase gene (SOD1) causing familial amyotrophic lateral sclerosis in a large Polish family. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 132-136.	2.3	5
36	New therapeutic targets for amyotrophic lateral sclerosis. Expert Opinion on Therapeutic Targets, 2011, 15, 127-143.	1.5	18

#	Article	IF	Citations
37	Mice with Mutation in Dynein Heavy Chain 1 Do Not Share the Same Tau Expression Pattern with Mice with SOD1-Related Motor Neuron Disease. Neurochemical Research, 2011, 36, 978-985.	1.6	9